Microbot Medical (NASDAQ:MBOT – Get Free Report) had its price objective decreased by investment analysts at Citizens Jmp from $2.50 to $2.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has a “market outperform” rating on the biotechnology company’s stock. Citizens Jmp‘s price objective points to a potential upside of 210.37% from the company’s current price.
Several other research analysts also recently issued reports on MBOT. Wall Street Zen downgraded shares of Microbot Medical from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 24th. Zacks Research lowered shares of Microbot Medical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 20th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Microbot Medical in a report on Wednesday, October 21st. B. Riley Financial started coverage on shares of Microbot Medical in a research note on Friday, September 11th. They set a “buy” rating and a $4.00 target price for the company. Finally, Citigroup started coverage on Microbot Medical in a report on Friday, October 23rd. They set a “market outperform” rating on the stock. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $5.00.
Check Out Our Latest Analysis on Microbot Medical
Microbot Medical Trading Down 34.2%
MBOT stock opened at $0.64 on Tuesday. The company has a market capitalization of $43.28 million, a P/E ratio of -2.48 and a beta of 1.07. Microbot Medical has a twelve month low of $0.52 and a twelve month high of $2.85. The business has a 50 day simple moving average of $1.15 and a 200-day simple moving average of $1.79.
Microbot Medical (NASDAQ:MBOT – Get Free Report) last announced its earnings results on Friday, November 13th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The firm had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.01 million. Research analysts predict that Microbot Medical will post -0.30 EPS for the current fiscal year.
Institutional Trading of Microbot Medical
Several hedge funds have recently made changes to their positions in MBOT. CTC Alternative Strategies Ltd. purchased a new position in Microbot Medical during the first quarter worth about $28,000. Private Advisor Group LLC acquired a new stake in shares of Microbot Medical in the 1st quarter valued at approximately $54,000. Cetera Investment Advisers lifted its holdings in shares of Microbot Medical by 44.7% in the 1st quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 13,099 shares during the period. Finally, Bank of America Corp DE boosted its stake in shares of Microbot Medical by 1,688.1% in the first quarter. Bank of America Corp DE now owns 75,799 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 71,560 shares in the last quarter. Institutional investors and hedge funds own 16.30% of the company’s stock.
Microbot Medical Company Profile
Microbot Medical is a medical-device company developing robotic technologies for endovascular procedures. Its work focuses on tools intended to help physicians navigate blood vessels and perform minimally invasive interventions. The company’s lead platform, LIBERTY, is a remotely operated robotic system designed for endovascular procedures. The system is intended to work with guidewires and catheters and to support physicians in controlling these devices during treatment. Microbot Medical is based in the United States and has roots in Israel.
Further Reading
- Five stocks we like better than Microbot Medical
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.
